BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Passler M, Taube ET, Sehouli J, Pietzner K. Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report. World J Clin Oncol 2019; 10(7): 247-255 [PMID: 31396474 DOI: 10.5306/wjco.v10.i7.247]
URL: https://www.wjgnet.com/2218-4333/full/v10/i7/247.htm
Number Citing Articles
1
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Ramy Gadalla, Matthew S Block, Andrea Jewell, Stephanie L Gaillard, Michael McHale, Carolyn McCourt, Sarah Temkin, Eugenia Girda, Floor J Backes, Theresa L Werner, Linda Duska, Siobhan Kehoe, Ilaria Colombo, Lisa Wang, Xuan Li, Rachel Wildman, Shirin Soleimani, Scott Lien, John Wright, Trevor Pugh, Pamela S Ohashi, David G Brooks, Gini F Fleming. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancerJournal for ImmunoTherapy of Cancer 2022; 10(3): e004233 doi: 10.1136/jitc-2021-004233
2
Anna Pawłowska, Wiktoria Skiba, Dorota Suszczyk, Weronika Kuryło, Joanna Jakubowicz-Gil, Roman Paduch, Iwona Wertel. The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer PatientsCancers 2022; 14(23): 5757 doi: 10.3390/cancers14235757
3
Alessia Cimadamore, Liang Cheng, Marina Scarpelli, Antonio Lopez-Beltran, Veronica Mollica, Rodolfo Montironi, Francesco Massari. Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76European Urology 2021; 79(1): e17 doi: 10.1016/j.eururo.2020.09.047
4
Anna Pawłowska, Anna Rekowska, Weronika Kuryło, Anna Pańczyszyn, Jan Kotarski, Iwona Wertel. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint InhibitorsInternational Journal of Molecular Sciences 2023; 24(13): 10859 doi: 10.3390/ijms241310859